Citations

Clear

71 citation(s) found for "Mini, GK".

Comparison of the Mini Parasep SF®, ParaPak SpinCon®, and Paradevice® fecal filtration and concentration devices for microscopic and AI-assisted detection of intestinal parasites
Morris, Heather, Pritt, Bobbi S. , Pritt, Bobbi S , Morris, Heather

Mayo Clinic

No container title available | June 4, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.02.26354769 Get It

Abstract Effective filtration and concentration of stool specimens is an essential pre-analytical step for reducing fecal debris and improving organism recovery using microscopy-based ova and parasite (O&P) examination. This study evaluated three commercially available fecal sedimentation-based filtration/concentration systems – ParaPak SpinCon® (Meridian Bioscience), Mini Parasep SF® (Apacor), and the newly-available Paradevice® (Reingenuity) – for qualitative parasite detection and workflow logistics using conventional and artificial intelligence (AI)-assisted microscopy. Forty clinical stool specimens (20 parasite-positive and 20 parasite-negative) were processed with the 3 devices, and the resultant 120 wet mount and 120 trichrome-stained smear preparations were examined using conventional microscopy. Trichrome-stained slides were also scanned at 40x magnification using a Hamamatsu® NanoZoomerS360® flatbed digital slide scanner and images were analyzed using the Techcyte® Fusion Human Fecal Trichrome AI algorithm. Positive and indeterminate digital findings were confirmed by conventional glass slide microscopy. Slides and digital images were reviewed in a blinded manner. Concordance was assessed among the 360 initial evaluations (microscopy and AI-assisted), and discrepant parasitology results were resolved through re-review and specimen reprocessing as needed. Final qualitative agreement across slide/image evaluations using all three concentration systems was 100%. Minor discrepancies in protozoan and white/red blood cell detection/identification were noted in 5 and 7 cases, respectively, and likely reflected sampling and observer variability. While the three concentration systems produced equivalent qualitative results, the Paradevice® and Mini Parasep SF® offered the most streamlined workflows. These findings support the Paradevice® and Mini Parasep SF® as efficient, analytically equivalent systems that are compatible with traditional and AI-assisted O&P workflows. Importance Microscopy-based examination of stool specimens remains an important diagnostic tool for intestinal parasitic infections. Filtration and concentration methods improve test performance by increasing organism recovery and reducing obscuring fecal debris prior to evaluation. These methods may also facilitate the preparation of thin monolayer trichrome-stained slides for digital scanning and automated parasite detection. Because many clinical laboratories rely on commercial filtration and concentration systems, supply chain disruptions, product shortages, and manufacturer recalls threaten testing continuity, underscoring the need for validated alternatives. This study demonstrates that multiple commercially available concentration systems provide equivalent parasite detection while supporting both conventional microscopy and emerging digital workflows. These findings provide laboratories with evidence-based alternatives that enhance operational resilience without compromising diagnostic performance.
Robotic-Assisted Single-Position Lateral Mini-Open Upper Lumbar Corpectomy with Posterior Percutaneous Pedicle Screw Fixation: A Technical Note with Illustrative Case Series
Iyer, Harshvardhan , Llano, Juan P. Navarro-Garcia de, Wang, Eric, Johnson, Walter R., Sastry, Rahul A. , Ramos, Rafael de La Garza, Sampath, Prakash , Gokaslan, Ziya L., Oyelese, Adetokunbo A. , Ramos, Rafael De la Garza , Llano, Juan P Navarro-Garcia de , De la Garza Ramos, Rafael , Navarro-Garcia de Llano, Juan P , Iyer, Harshvardhan G , Wang, Elaina J., Gokaslan, Ziya L., Akinduro, Oluwaseun O.

Mayo Clinic

Applied Sciences | April 6, 2026 | Volume: 16 | Issue: 7 | Pages: 3501

10.3390/app16073501 Get It

Management of unstable upper lumbar fractures with corpectomy and posterior fixation is technically demanding, and conventional workflows may require intraoperative repositioning, increasing operative complexity. Lateral mini-open upper lumbar corpectomy (LMULC) paired with robotic-assisted (RA) posterior percutaneous pedicle screw fixation (PPPSF) can be performed in a single position to facilitate ventral spinal decompression and stabilization in the anatomically constrained upper lumbar spine. In this study, we describe the operative technique and report four illustrative cases of unstable L1 or L2 fractures treated with single-position LMULC, RA-PPPSF, and short-segment fusion. Clinical, radiological, intraoperative variables and postoperative outcomes were evaluated. The mean age was 52.3 ± 17.7 years. The median operation time was 314 min (range 268–361 min); the median estimated blood loss (EBL) was 225 mL (range 100–400 mL). The median preoperative kyphosis was 10.15° (range 8.4–14.6°), the median postoperative kyphosis measured 6.65° (range 1.7–10.8°) and the median correction achieved was 3.5° (range −2.4–12.9°). The median visual analog scale (VAS) pain score reduced from 7 (range 7–9) preoperatively to 4.5 (range 2–6) postoperatively at discharge. At a median follow-up of 12 months (range 6–15 months), all patients had uncomplicated recoveries, demonstrated solid fusion on imaging, and reported favorable MacNab outcomes. Single-position LMULC with RA-PPPSF was technically feasible in this preliminary illustrative series and resulted in favorable clinical and radiographic outcomes. However, further studies in larger cohorts are warranted to help confirm these findings and better define the potential advantages and limitations of this technique.
Mini-Galaxy: Rethinking Complex Human Diseases Through the Lens of Systems Biology and Multilayered AI Network Perspectives
Correia, Cristina Belo , Ung, Choong Yong , Zhang, Z, Blissenbach, Easton , Zhu, Shizhen , Billadeau, Daniel D. , Li, Hu, Zhang, Zhuofei, Correia, Cristina, Loh, Yuin‐Han

Mayo Clinic

International Journal of Molecular Sciences | March 31, 2026 | Volume: 27 | Issue: 7 | Pages: 3161

10.3390/ijms27073161 | PMID 41977346 Get It

Human diseases are complex and arise from the coordinated action of multiple genes and their protein products. Genes’ behaviors extend beyond genetic variants, mutations, and differential expressions. Their coordinated activity across biological scales (molecules, cells, tissues, organs) produces emergent behaviors that shape health and disease. These emergent behaviors span time and space and are often hard to measure directly from observation when using standard experimental measurements. Yet these “hidden” or latent gene characteristics can be powerful drivers of disease. We propose a Mini-Galaxy Model (MGM), a systems-level AI-driven network framework that models cells as “mini-galaxies” composed of multilayered biological information, with each layer encoding a different dimension of genes’ behavior. Here, we delineate a strategy on how to construct and compare MGMs across health and disease and map their etiological relatedness. We also operationalize the MGM as a discovery platform for translational medicine, offering modules to allow target prioritization and editing. By reframing human diseases as the result of emergent behavior of multilayered multimode biological networks and their perturbations, the MGM yields actionable rules to streamline biomarker discovery, guide target selection and enable rational design of combinatorial interventions, and accelerate drug repurposing.
Early to Mature, Early to Detect: Artificial Intelligence in the Risk Prediction and Diagnosis of Precocious Puberty
Chavan, Manisha, Tabassum, Sameena, Joshi, Divya Dinesh, Boppana, Kusalik , Banu, Nasreen, Kayarkar, Riya, Chauhan, Kalp, Yerrapragada, Gayathri, Elangovan, Poonguzhali, Shariff, Mohammed Naveed , Natarajan, T.K. , Janarthanan, Jayarajasekaran, Agarwal, Shreshta, Wilson, Sancia Mary Jerold, Virmani, Mini , Ghosh, Atishya, Serwaah, Mimi Adu , Karuppiah, Shiva Sankari, Gopalakrishnan, Keerthy, Sood, Divyanshi, Rapolu, Swetha, Cherukuri, Swathi Priya , Arunachalam, S., Arunachalam, Shivaram P. , Elangovan, Poonguzhali , Elangovan, Poonguzhali , Arunachalam, S P , Natarajan, Thangeswaran , Shariff, Mohammad Naveed , Agarwal, Shreshta , Tabassum, Sameena , Banu, Nasreen, Yerrapragada, Gayathri

Mayo Clinic

Reproductive Medicine | February 13, 2026 | Volume: 7 | Issue: 1 | Pages: 9

10.3390/reprodmed7010009 Get It

Background/Objectives: Precocious puberty (PP), defined as the onset of secondary sexual characteristics before 8 years in girls and 9 years in boys, is associated with psychosocial distress, compromised adult height, and long-term metabolic risk. Early identification remains challenging, as current diagnostic approaches are largely reactive and rely on invasive or resource-intensive testing. This narrative review examines how artificial intelligence (AI) can support earlier risk prediction and detection of PP through integration of clinical, hormonal, imaging, lifestyle, and environmental data. Methods: A narrative literature review was conducted using PubMed, Scopus, Embase, Web of Science, and Google Scholar to identify relevant studies published between 2005 and 2025. Eligible studies included original research and high-quality reviews that examined AI-based approaches, such as machine learning and deep learning, in pediatric endocrinology, particularly for the prediction or diagnosis of central or peripheral precocious puberty. Studies incorporating clinical, hormonal, radiological, lifestyle, environmental, or multi-omics data relevant to AI modeling were included. Results: AI models, including XGBoost, random forest, convolutional neural networks, and regression-based approaches, have demonstrated potential utility in predicting central precocious puberty using hormonal, imaging, and growth data. Reported applications include automated bone age assessment, lifestyle and dietary risk stratification, and exploratory use of wearable-derived behavioral data. However, progress is limited by small pediatric datasets, population bias, limited interpretability, and unresolved ethical challenges related to privacy, consent, and equity. Conclusions: Artificial intelligence represents a promising decision-support approach for earlier, non-invasive, and individualized risk assessment in precocious puberty. Future progress will depend on the integration of longitudinal, multimodal data, the development of ethical models, and interdisciplinary collaboration among pediatric endocrinologists, data scientists, and public health stakeholders.
Treatment patterns in patients aged 80+ years with LBCL: Propensity score analysis reveals comparable outcomes between R-CHOP and R-mini-CHOP
Vodička, Prokop , Masar, Michal, Lossos, Izidore S., Benešová, Kateřina , Polgárová, Kamila , Kořen, Jan , Patel, Dilan A. , Martin, Peter , Sálková, J, Dlouhá, Jitka, Cohen, Jonathon B. , Blahovcová, Petra, Mwangi, Raphael , Jakša, Radek , Nowakowski, Grzegorz S. , Friedberg, Jonathan W. , Flowers, Christopher R. , Reagan, Patrick Michael , Lossos, Izidore S. , Mou, Eric , Jaye, David L. , Maláriková, Diana , Nze, Chijioke , Karban, Josef , Feldman, Andrew L. , Habermann, Thomas M. , Maurer, Matthew J. , Klánová, Magdalena , Klener, Pavel , Trněný, Marek , Cerhan, James R. , Vodicka, Prokop

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 5448-5448

10.1182/blood-2025-5448 Get It

Abstract Introduction Although chemo-free regimens are increasingly used in elderly patients with large B-cell lymphoma (LBCL), most still receive conventional chemoimmunotherapy. Patients up to 75–80 years old are usually treated with full-dose R-CHOP, while 80+ patients receive the attenuated R-miniCHOP regimen as standard of care. Prior studies have shown that in patients aged 65+ years, R-CHOP was associated with improved survival based on propensity score matching (PSM) analysis (Al-Sarayfi, Am J Hematol, 2023), though this did not include comorbidity data. Furthermore, no formal studies have focused specifically on 80+ patients. We aimed to perform a PSM comparison of R-CHOP versus R-miniCHOP to better inform treatment decisions in this population. Methods We harmonized and pooled data from 237 LBCL patients receiving chemotherapy with rituximab (out of all 263 80+ patients) from the prospective LEO cohort (USA, n=147; 2015–2020) and NiHiL registry (Czech Republic, single center, n=116; 2010–2023). Of them, 205 (86%) receiving anthracycline(A)-based regimens were included. Baseline characteristics, comorbidities, treatments, and outcomes were collected. PSM (1:1, caliper 0.2) was performed to compare R-CHOP and R-miniCHOP using age, ECOG performance status (PS), clinical stage, lactate dehydrogenase (LDH), and major comorbidities (heart disease, history of stroke, and other recent cancer) as matching variables. The endpoints were overall survival (OS), event-free survival (EFS), and lymphoma-specific survival (LSS, defined as death attributed to lymphoma progression). Results Among 205 A-treated patients, median age was 83 years (range 80–99); 30% had ECOG PS 2–4, 67% clinical stage III–IV, 34% ≥2 involved extranodal sites, 59% elevated LDH, and 58% had International Prognostic Index (IPI) scores 3–5. Median follow-up was 5.5 years; median OS and EFS were 4.1 and 3.4 years, resp. A-based regimens comprised full-dose R-CHOP-like (n=79; 39%; R-CHOP n=74, DA-EPOCH-R n=5) and R-miniCHOP (n=126; 61%). Patients receiving R-CHOP-like regimens had more favorable baseline characteristics (median age 82 vs 83 years, P=0.04; ECOG PS 2–4: 16% vs 39%, P<0.01; IPI 3–5: 46% vs 66%, P=0.03) and a lower, though not statistically significant, comorbidity burden (mean 1.14 vs 1.39; heart disease 35% vs 45%, P=0.22; history of stroke 4% vs 6%, P=0.64; other cancer 6% vs 5%, P=0.87). R-CHOP-like regimens vs R-miniCHOP had superior OS (median 6.3 vs 3.4 years; HR=0.61, 95% CI 0.42–0.90; P=0.01) and EFS (median 5.3 vs 2.1 years; HR=0.58, 95% CI 0.40–0.83; P<0.01), with no significant difference in LSS (2-year 89% vs 82%, HR=0.77, 95% CI 0.39–1.54, P=0.46). To mitigate selection bias, we performed PSM on patients with available baseline characteristics treated with R-CHOP (n=69) and R-miniCHOP (n=121), resulting in 63 matched pairs. Matched cohorts were well-balanced on age (median 82 years in both cohorts; P=0.68), ECOG PS 2–4 (17% vs 19%; P=0.82), IPI 3–5 (52% vs. 59%; P=0.41), and comorbidity burden (mean 1.10 vs. 1.29; P=0.30). The presence of heart disease (40% in both cohorts), history of stroke (5% vs 6%), and cancer (5% vs 6%) were similar. Survival modestly favored R-CHOP, but differences were not significant: median OS 5.3 vs 3.5 years (HR=0.73; 95% CI 0.46–1.15; P=0.17), median EFS 3.8 vs 2.8 years (HR=0.76; 95% CI 0.49–1.18; P=0.23), and 2-year LSS 88% vs 84% (HR=1.09; 95% CI 0.45–2.63; P=0.85). Treatment-related mortality was similar in both cohorts (16%). Among R-miniCHOP patients, survival outcomes did not differ between matched (n=63) and unmatched (n=63) groups (OS P=0.72; EFS P=0.23; LSS P=0.27). Unmatched (n=16) R-CHOP patients had a trend toward improved survival compared to matched (n=63) individuals (OS P=0.10; EFS P=0.049; LSS P=0.24). Conclusion This is the first PSM-based analysis comparing R-CHOP and R-miniCHOP in LBCL patients 80+ years old. Despite inherent limitations of a non-randomized design and limited number of matched patients, our findings – derived from two prospective cohorts – suggest that R-miniCHOP may offer outcomes comparable to R-CHOP, particularly with respect to LSS. While these results support R-miniCHOP as an appropriate frontline option, treatment decisions remain highly individualized. These data may help inform clinical decision-making and provide a basis for designing future trials targeting this population, where R-miniCHOP could serve as a comparator arm. Funding: NU21-03-00411, U01 CA195568.
Final 60-Month Efficacy, Safety, and Kidney Stone Outcomes of a Phase 3 Trial of Lumasiran for Primary Hyperoxaluria Type 1 in Infants and Young Children
Sas, David J. , Michael, Mini , Frishberg, Yaacov, Ben‐Shalom, Efrat , Shasha‐Lavsky, Hadas , Sellier-Leclerc, A.L., Hogan, Julien, Du, W. J. , Murphy, Michael Desmond, Kaspar, Cristin , Magen, Daniella , Hayes, Wesley Nathan , Sellier‐Leclerc, Anne‐Laure , Hogan, Julien , Du, Weiming

Mayo Clinic

Journal of the American Society of Nephrology | October 23, 2025 | Volume: 36 | Issue: 10S | Pages: No page available

10.1681/asn.2025v7er7rv3 Get It

A Practical Guide to Developing and Troubleshooting Patient-Derived “Mini-Gut” Colorectal Organoids for Clinical Research
Balaya, Rex Devasahayam Arokia , Heydari, Zahra , Sarkar, Gobinda , Garcia, Edwin , Hoyos‐Vega, José M. de , Krueger, Eugene W. , Helgeson, Lauren, Revzin, Alexander , Ros, Alexandra , Pandey, Akhilesh , Boardman, Lisa, Devasahayam Arokia Balaya, Rex , Cruz Garcia, Estela Mariel , de Hoyos-Vega, Jose M , Krueger, Eugene W , Pandey, Akhilesh , Boardman, Lisa

Mayo Clinic

Methods and Protocols | October 13, 2025 | Volume: 8 | Issue: 5 | Pages: 121

10.3390/mps8050121 | PMID 41149804 Get It

Patient-derived organoids (PDOs) have emerged as powerful tools in personalized medicine applicable to both non-malignant conditions and to cancer, where they are increasingly used for personalized drug screening and precision treatment strategies in part due to their ability to replicate tumor heterogeneity. They also serve as study model systems to understand disease mechanisms, pathways, and the impact of ex vivo exposures. We present a detailed step-by-step protocol for generating organoids from normal crypts, polyps, and tumors, including methods for tissue processing, crypt isolation, culture establishment, and the transition from basolateral to apical-out polarity for co-culture and exposure-based studies. The protocol also includes immunofluorescence staining procedures for cellular characterization and quality control measures. Our standardized approach successfully generates organoids from diverse colorectal tissues with high efficiency and reproducibility. This comprehensive guide addresses common technical challenges and provides troubleshooting strategies to improve success rates across different sample types. We believe that this resource will enhance reproducibility in organoid research and expand their utility in translational applications, particularly for personalized medicine approaches in colorectal cancer.
Mini‐lattice radiation therapy: A treatment planning approach to miniaturize spatially fractionated lattice radiation therapy using a clinical linear accelerator
Hara, Daiki , Abou‐Mourad, Houssam, Thull, Jack C., Laack, Nadia N., Self, Chelsea, Fernandez‐Rodriguez, Alfredo , Prezado, Yolanda , Tseung, Hok Seum Wan Chan, Breen, William G. , Mutter, Robert W. , Antolak, John A. , Tseung, Hok Seum W C, Lester, Scott C. , Park, Sean S. , Grams, Michael P.

Mayo Clinic

Medical Physics | September 29, 2025 | Volume: 52 | Issue: 10 | Pages: No page available

10.1002/mp.70027 | PMID 41016844 Get It

Abstract Background Spatially fractionated radiation therapy (SFRT) is a technique that delivers heterogenous dose distributions consisting of alternating regions of high dose “peaks” and low dose “valleys”. Current delivery methods for SFRT using megavoltage x‐rays usually treat large and bulky tumors with brass grid or volumetric modulated arc therapy (VMAT) lattice techniques. The size and spacing of high dose regions in these approaches are typically on the order of centimeters. However, multiple studies have suggested that decreasing these dimensions may improve the therapeutic ratio. Furthermore, a more compact approach to SFRT would allow for a greater number of high dose regions within the tumor, as well as application to smaller and more irregularly shaped targets thereby increasing the number of patients that could benefit from SFRT. Purpose This study describes the commissioning and first patient treatment using mini‐lattice radiation therapy (MLRT). MLRT uses a clinical linear accelerator and decreases the size and spacing of standard lattice SFRT by using individual multileaf collimator (MLC) leaves to deliver 5 mm wide high dose regions. Methods MLRT plans were created in the Varian Eclipse treatment planning system for a Varian Truebeam equipped with Millennium 120 MLCs. MLRT uses 6 MV Flattening Filter Free high dose rate and the width of individual MLCs to define 5 mm by 5 mm openings separated by closed MLCs to deliver alternating opened and blocked regions. Dynamic conformal arcs were used to conform MLCs to 4 mm spherical mini‐lattice structures in the gross tumor volume (GTV). A MLRT‐specific beam model was commissioned to accurately model the small MLRT fields. Film measurements were performed to assess the accuracy of MLRT plans calculations. Plans for seven treatment sites in different parts of the body for retrospective patient candidates were created with varying numbers of mini‐lattices and separation distances to assess the impact of varying these parameters on treatment dose metrics. MLRT was used for the first time to treat a patient with two fractions of MLRT. Results The AcurosXB calculation algorithm with modified x and y spot sizes, dosimetric leaf gap, transmission factor, and output factor table was used to generate a beam model for accurate MLRT calculations. The MLRT‐specific beam model resulted in gamma passing rates (1%/0.5 mm criteria) of 90%–99% for retrospective patient MLRT film measurements. Dose volume histogram statistics, equivalent uniform dose, and mean dose showed a higher number of mini‐lattices with smaller separation increased the dose to the GTV and surrounding tissue. Separation distances between mini‐lattices did not impact plan heterogeneity as measured by D10%/D90%. The first patient treated with the MLRT technique reported pain relief, had stable disease, and no acute toxicities following both fractions. Conclusions MLRT is feasible using clinical linear accelerators and existing radiation oncology infrastructure. It enables targeting smaller tumors with SFRT, allows for a greater number of high dose regions within the target compared to standard VMAT lattice techniques, and may be a useful technique for challenging treatment scenarios.
Impact of elective surgery on tumor necrosis factor‐α, interleukin‐6 and quality of life in uncomplicated diverticular disease
Sassun, Richard , Roufael, Francesca, Crippa, Jacopo , Achilli, Pietro , Dinuzzi, Vincenza Paola , Maggioni, Dario, Costanzi, Andrea , Siracusa, Claudia , Leoni, Valerio , Mari, Giulio , Achilli, P , Larson, David Wesley, Crippa, J , Sassun, Richard , Magistro, Carmelo , Bertoglio, Camillo Leonardo , Montroni, Isacco , Spinelli, Antonino , Dominici, Roberto , Larson, David W.

Mayo Clinic

Colorectal Disease | June 10, 2025 | Volume: 27 | Issue: 6 | Pages: No page available

10.1111/codi.70132 | PMID 40491034 Get It

Abstract Aim Growing evidence suggests that immune/inflammatory pathways play a crucial role in the persistence of symptoms in diverticular disease (DD). We hypothesize that chronic diverticulitis triggers a self‐sustained inflammatory status which can be detected by measuring the levels of tumor necrosis factor‐α (TNF‐α) and interleukin‐6 (IL‐6). The aim of this study was to investigate the systemic levels of TNF‐α and IL‐6 before and after elective surgery in patients with DD, and their relationship with the gastrointestinal quality of life index (GIQLI) score. Method This prospective multicentric study enrolled patients from the Diverticular Disease Registry (DDR‐Trial, NCT04907383). All adult patients diagnosed with symptomatic uncomplicated diverticular disease (SUDD), uncomplicated recurrent diverticulitis (URD) and smouldering diverticulitis (SmD) between 1st December 2022 and 31st December 2023 were included in this study. Exclusion criteria were as follows: no surgery, a concurrent chronic immunomodulated systemic disease, a SARS‐CoV‐2‐positive test in the previous 12 months, a history of cancer in the previous 5 years, patients treated with immunomodulators, an American Society of Anesthesiologists category of class IV, and complicated acute diverticulitis. Results Seventy‐two patients were included: 52 (72%) with URD, 11 (15%) with SUDD, and nine (13%) with SmD. The median postsurgery – presurgery (Δ)IL‐6 and ΔTNF‐α levels were −16.8 and −17.3 pg/mL, respectively ( p < 0.001 for both; Wilcoxon test). Spearman correlation revealed a significant, negative association between the ΔGIQLI and the ΔIL‐6, as well as the ΔTNF‐α ( p < 0.001 for both). Greater reduction in the levels of IL‐6 and TNF‐α following surgery are associated with higher GIQLI scores postoperatively. Conclusion Patients with chronic diverticulitis may experience persistent systemic inflammation driven by a colonic trigger. Surgical removal of this trigger appears to enhance GIQLI outcomes reducing IL‐6 and TNF‐α across surgery.
Mini-invasive Anterior Petrosal Intertentorial Approach for Trigeminal Neuralgia: Rationale and Limits of the Technique
Giammattei, Lorenzo , Peters, David R. , Mellal, Amine , Starnoni, Daniele, Daniel, Roy Thomas , Peters, D , Squair, Jordan W. , Fava, Arianna , Aureli, Viviana , Pistocchi, Silvia

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | April 15, 2025 | Volume: 87 | Issue: 02 | Pages: 144-150

10.1055/a-2587-6267 | PMID 41808976 Get It

Abstract The retrosigmoid approach (RSA) is considered the standard surgical choice to address a neurovascular conflict involving the trigeminal nerve. The subtemporal transtentorial approach (STA) represents the main alternative. We describe here the mini-invasive anterior petrosal intertentorial approach with a view to reduce complications associated with the standard STA. Mini-invasive anterior petrosal intertentorial approach (M-APIA) was described for a case of refractory trigeminal neuralgia. This approach includes a very limited amount of drilling of the petrous ridge to expose the posterior fossa dura and the superior petrosal sinus to facilitate the subsequent tentorial peeling. Tentorial peeling enables to develop an intertentorial plane between the temporal tentorial leaf (TTL) and the posterior fossa tentorial leaf (PFTL). A linear incision over the posterior fossa dura and the PFTL offers a wide exposure of the neurovascular conflict. M-APIA enables to expose the root entry zone (REZ) of the trigeminal nerve without exposing the temporal lobe or the cerebellum. M-APIA can be considered as a safe alternative to the RSA or STA for trigeminal microvascular decompression (MVD), especially for select cases. Additional studies are needed for a better understanding of its advantages and disadvantages.